Overview

Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis

Status:
Recruiting
Trial end date:
2024-03-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in patients with active ankylosing spondylitis
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Suzhou Suncadia Biopharmaceuticals Co., Ltd.